Do analysts rate AMRN or SVRA?

Savara has a consensus price target of $10.14, suggesting a potential upside of 74.73%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Savara 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has higher earnings & valuation, AMRN or SVRA?

Amarin has higher revenue and earnings than Savara. Amarin is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.40 -$38.80M -$0.99 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is AMRN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% Savara N/A -87.19% -66.42%

Does the media prefer AMRN or SVRA?

In the previous week, Savara had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Savara and 2 mentions for Amarin. Savara's average media sentiment score of 0.84 beat Amarin's score of -0.13 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate WVE or AMRN?

WAVE Life Sciences presently has a consensus price target of $22.53, indicating a potential upside of 269.03%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score WAVE Life Sciences 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.94 Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, WVE or AMRN?

Amarin has higher revenue and earnings than WAVE Life Sciences. Amarin is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 28.15 -$204.38M -$1.09 N/A Amarin $213.65M 1.40 -$38.80M -$0.99 N/A

Is WVE or AMRN more profitable?

Amarin has a net margin of -14.56% compared to WAVE Life Sciences' net margin of -309.73%. Amarin's return on equity of -0.20% beat WAVE Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -309.73% -50.36% -40.06% Amarin -14.56% -0.20% -0.14%

Does the media favor WVE or AMRN?

In the previous week, WAVE Life Sciences had 17 more articles in the media than Amarin. MarketBeat recorded 19 mentions for WAVE Life Sciences and 2 mentions for Amarin. WAVE Life Sciences' average media sentiment score of -0.06 beat Amarin's score of -0.13 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AMRN or SDGR?

Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 8.99%. Given Schrodinger's higher possible upside, analysts clearly believe Schrodinger is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Schrodinger 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation and earnings, AMRN or SDGR?

Amarin has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.40 -$38.80M -$0.99 N/A Schrodinger $255.87M 5.36 -$103.26M -$0.74 N/A

Is AMRN or SDGR more profitable?

Amarin has a net margin of -14.56% compared to Schrodinger's net margin of -20.98%. Amarin's return on equity of -0.20% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% Schrodinger -20.98% -16.37% -8.19%

Does the media favor AMRN or SDGR?

In the previous week, Schrodinger had 13 more articles in the media than Amarin. MarketBeat recorded 15 mentions for Schrodinger and 2 mentions for Amarin. Schrodinger's average media sentiment score of 0.57 beat Amarin's score of -0.13 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Schrodinger 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AMRN or CRVS?

Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 145.12%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Corvus Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Does the media favor AMRN or CRVS?

In the previous week, Corvus Pharmaceuticals had 7 more articles in the media than Amarin. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 2 mentions for Amarin. Amarin's average media sentiment score of -0.13 beat Corvus Pharmaceuticals' score of -0.17 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AMRN or MGTX?

MeiraGTx has a consensus target price of $26.00, indicating a potential upside of 96.46%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 MeiraGTx 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better valuation & earnings, AMRN or MGTX?

Amarin has higher revenue and earnings than MeiraGTx. Amarin is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.40 -$38.80M -$0.99 N/A MeiraGTx $81.39M 15.06 -$114.20M -$1.48 N/A

Is AMRN or MGTX more profitable?

Amarin has a net margin of -14.56% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% MeiraGTx -151.12% N/A -54.96%

Does the media prefer AMRN or MGTX?

In the previous week, Amarin and Amarin both had 2 articles in the media. MeiraGTx's average media sentiment score of 0.00 beat Amarin's score of -0.13 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Amarin (AMRN) Competitors

$14.28 -0.08 (-0.52%)

As of 11:15 AM Eastern

Compare

AMRN vs. SVRA, WVE, SDGR, CRVS, and MGTX

Should you buy Amarin stock or one of its competitors? MarketBeat compares Amarin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amarin include Savara (SVRA), WAVE Life Sciences (WVE), Schrodinger (SDGR), Corvus Pharmaceuticals (CRVS), and MeiraGTx (MGTX).

How does Amarin compare to Savara?

Amarin (NASDAQ:AMRN) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Savara had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Savara and 2 mentions for Amarin. Savara's average media sentiment score of 0.84 beat Amarin's score of -0.13 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amarin has higher revenue and earnings than Savara. Amarin is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Savara has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Savara	N/A	-87.19%	-66.42%

Savara has a consensus price target of $10.14, suggesting a potential upside of 74.73%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Savara has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

22.3% of Amarin shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Savara beats Amarin on 10 of the 15 factors compared between the two stocks.

How does Amarin compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amarin has higher revenue and earnings than WAVE Life Sciences. Amarin is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	28.15	-$204.38M	-$1.09	N/A
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A

WAVE Life Sciences presently has a consensus price target of $22.53, indicating a potential upside of 269.03%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Amarin has a net margin of -14.56% compared to WAVE Life Sciences' net margin of -309.73%. Amarin's return on equity of -0.20% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Amarin	-14.56%	-0.20%	-0.14%

WAVE Life Sciences has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

In the previous week, WAVE Life Sciences had 17 more articles in the media than Amarin. MarketBeat recorded 19 mentions for WAVE Life Sciences and 2 mentions for Amarin. WAVE Life Sciences' average media sentiment score of -0.06 beat Amarin's score of -0.13 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

WAVE Life Sciences beats Amarin on 9 of the 16 factors compared between the two stocks.

How does Amarin compare to Schrodinger?

Amarin (NASDAQ:AMRN) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Amarin has a net margin of -14.56% compared to Schrodinger's net margin of -20.98%. Amarin's return on equity of -0.20% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Schrodinger	-20.98%	-16.37%	-8.19%

Schrodinger has a consensus price target of $20.25, suggesting a potential upside of 8.99%. Given Schrodinger's higher possible upside, analysts clearly believe Schrodinger is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Amarin has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
Schrodinger	$255.87M	5.36	-$103.26M	-$0.74	N/A

22.3% of Amarin shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Schrodinger had 13 more articles in the media than Amarin. MarketBeat recorded 15 mentions for Schrodinger and 2 mentions for Amarin. Schrodinger's average media sentiment score of 0.57 beat Amarin's score of -0.13 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Schrodinger	3 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Schrodinger beats Amarin on 10 of the 17 factors compared between the two stocks.

How does Amarin compare to Corvus Pharmaceuticals?

Amarin (NASDAQ:AMRN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

In the previous week, Corvus Pharmaceuticals had 7 more articles in the media than Amarin. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 2 mentions for Amarin. Amarin's average media sentiment score of -0.13 beat Corvus Pharmaceuticals' score of -0.17 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 145.12%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

22.3% of Amarin shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Corvus Pharmaceuticals has lower revenue, but higher earnings than Amarin. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Summary

Corvus Pharmaceuticals beats Amarin on 10 of the 15 factors compared between the two stocks.

How does Amarin compare to MeiraGTx?

Amarin (NASDAQ:AMRN) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

22.3% of Amarin shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amarin has a net margin of -14.56% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
MeiraGTx	-151.12%	N/A	-54.96%

Amarin has higher revenue and earnings than MeiraGTx. Amarin is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
MeiraGTx	$81.39M	15.06	-$114.20M	-$1.48	N/A

Amarin has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

In the previous week, Amarin and Amarin both had 2 articles in the media. MeiraGTx's average media sentiment score of 0.00 beat Amarin's score of -0.13 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has a consensus target price of $26.00, indicating a potential upside of 96.46%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

MeiraGTx beats Amarin on 10 of the 15 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRN vs. The Competition

Export

Metric	Amarin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$300.44M	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-14.47	788.46	269.91	24.87
Price / Sales	1.40	969.81	654.69	108.21
Price / Cash	39.78	15.12	28.89	37.44
Price / Book	0.65	10.37	11.40	6.45
Net Income	-$38.80M	$2.77B	$3.45B	$347.50M
7 Day Performance	1.03%	2.26%	3.66%	3.77%
1 Month Performance	-4.00%	-1.28%	-0.49%	-0.40%
1 Year Performance	-4.70%	191.26%	77.51%	23.55%

Amarin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRN Amarin	1.359 of 5 stars	$14.29 -0.5%	N/A	-4.2%	$300.44M	$213.65M	N/A	360
SVRA Savara	2.1911 of 5 stars	$5.43 -1.5%	$10.14 +86.8%	+120.8%	$1.13B	N/A	N/A	20	Positive News Upcoming Earnings High Trading Volume
WVE WAVE Life Sciences	3.113 of 5 stars	$5.92 +1.9%	$26.41 +346.1%	-24.6%	$1.12B	$42.73M	N/A	240
SDGR Schrodinger	1.614 of 5 stars	$15.28 +2.1%	$20.25 +32.5%	-5.5%	$1.11B	$254.91M	N/A	790	Earnings Report Analyst Upgrade
CRVS Corvus Pharmaceuticals	2.9005 of 5 stars	$12.92 -1.1%	$33.33 +158.0%	+223.0%	$1.10B	N/A	N/A	30	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amarin (AMRN) Competitors